Literature DB >> 26914862

Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.

Thazha P Prakash1, Jinghua Yu1, Michael T Migawa1, Garth A Kinberger1, W Brad Wan1, Michael E Østergaard1, Recaldo L Carty1, Guillermo Vasquez1, Audrey Low1, Alfred Chappell1, Karsten Schmidt1, Mariam Aghajan1, Jeff Crosby1, Heather M Murray1, Sheri L Booten1, Jill Hsiao1, Armand Soriano1, Todd Machemer1, Patrick Cauntay1, Sebastien A Burel1, Susan F Murray1, Hans Gaus1, Mark J Graham1, Eric E Swayze1, Punit P Seth1.   

Abstract

The comprehensive structure-activity relationships of triantennary GalNAc conjugated ASOs for enhancing potency via ASGR mediated delivery to hepatocytes is reported. Seventeen GalNAc clusters were assembled from six distinct scaffolds and attached to ASOs. The resulting ASO conjugates were evaluated in ASGR binding assays, in primary hepatocytes, and in mice. Five structurally distinct GalNAc clusters were chosen for more extensive evaluation using ASOs targeting SRB-1, A1AT, FXI, TTR, and ApoC III mRNAs. GalNAc-ASO conjugates exhibited excellent potencies (ED50 0.5-2 mg/kg) for reducing the targeted mRNAs and proteins. This work culminated in the identification of a simplified tris-based GalNAc cluster (THA-GN3), which can be efficiently assembled using readily available starting materials and conjugated to ASOs using a solution phase conjugation strategy. GalNAc-ASO conjugates thus represent a viable approach for enhancing potency of ASO drugs in the clinic without adding significant complexity or cost to existing protocols for manufacturing oligonucleotide drugs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26914862     DOI: 10.1021/acs.jmedchem.5b01948

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

Review 1.  Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

Authors:  Alexandre J Debacker; Jon Voutila; Matthew Catley; David Blakey; Nagy Habib
Journal:  Mol Ther       Date:  2020-06-17       Impact factor: 11.454

Review 2.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

Review 3.  Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.

Authors:  Colton M Miller; Michael Tanowitz; Aaron J Donner; Thazha P Prakash; Eric E Swayze; Edward N Harris; Punit P Seth
Journal:  Nucleic Acid Ther       Date:  2018-02-09       Impact factor: 5.486

Review 4.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

5.  Whole-Body but Not Hepatic Knockdown of Chemerin by Antisense Oligonucleotide Decreases Blood Pressure in Rats.

Authors:  David J Ferland; Bridget Seitz; Emma S Darios; Janice M Thompson; Steve T Yeh; Adam E Mullick; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2018-02-21       Impact factor: 4.030

Review 6.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

7.  Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice.

Authors:  Mariam Aghajan; Sheri L Booten; Magnus Althage; Christopher E Hart; Anette Ericsson; Ingela Maxvall; Joseph Ochaba; Angela Menschik-Lundin; Judith Hartleib; Steven Kuntz; Danielle Gattis; Christine Ahlström; Andrew T Watt; Jeffery A Engelhardt; Brett P Monia; Maria Chiara Magnone; Shuling Guo
Journal:  JCI Insight       Date:  2019-06-20

8.  Different blood pressure responses in hypertensive rats following chemerin mRNA inhibition in dietary high fat compared to dietary high-salt conditions.

Authors:  David J Ferland; Emma D Flood; Hannah Garver; Steve T Yeh; Stanley Riney; Adam E Mullick; Gregory D Fink; Stephanie W Watts
Journal:  Physiol Genomics       Date:  2019-10-07       Impact factor: 3.107

9.  Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies.

Authors:  Erin S Morgan; Yvonne Tami; Kuolung Hu; Michela Brambatti; Adam E Mullick; Richard S Geary; George L Bakris; Sotirios Tsimikas
Journal:  JACC Basic Transl Sci       Date:  2021-05-03

10.  Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys.

Authors:  Colby S Shemesh; Rosie Z Yu; Hans J Gaus; Sarah Greenlee; Noah Post; Karsten Schmidt; Michael T Migawa; Punit P Seth; Thomas A Zanardi; Thazha P Prakash; Eric E Swayze; Scott P Henry; Yanfeng Wang
Journal:  Mol Ther Nucleic Acids       Date:  2016-05-10       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.